Multiple regression analysis indicated that baseline, 12 weeks HBsAg and the presence of cirrhosis were significant factors affecting the course of IFN treatment, and both were risk factors (β=7.27,4.27,10.91; p<0.05), i.e., the smaller the baseline and 12 weeks HBsAg in non-cirrhotic patients, the better the response to interferon, and the shorter the course of treatment to achieve clinical cure. This evidence concerns the gene IFNA1 and Cirrhosis.